14-3-3ζ Overexpression is Associated with Poor Prognosis in Ovarian Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: 14-3-3ζ regulates cell signaling, cell cycle progression, and apoptosis, and its overexpression is associated with disease recurrence and poor clinical outcomes in some solid tumors. However, its clinicopathological role in ovarian cancer is unknown. Our goal was to investigate whether 14-3-3ζ is associated with ovarian cancer prognosis. Materials and Methods: We examined 14-3-3ζ expression by immunohistochemistry in ovarian cancer tissues obtained from 88 ovarian cancer patients. The examined tissues were of various histologies and stages. 14-3-3ζ expression was also analyzed by western blot in seven ovarian cancer cell lines and a primary ovary epithelial cell line. Cell viability was measured using an MTS-based assay following cisplatin treatment. Results: Among the ovarian cancer samples, 53.4% (47/88) showed high 14-3-3ζ expression, and 14-3-3ζ overexpression was positively correlated with more advanced pathologic stages and grades. 14-3-3ζ overexpression was also significantly associated with poor disease-free survival (DFS) and overall survival (OS) of ovarian cancer patients. Median DFS and OS were 1088 and 3905 days, respectively, in the high 14-3-3ζ expression group, but not reached in the low 14-3-3ζ expression group (p=0.004 and p=0.033, log-rank test, respectively). Downregulating 14-3-3ζ by RNA interference in ovarian cancer cells led to enhanced sensitivityto cisplatin-induced cell death. Conclusion: 14-3-3ζ overexpression might be a potential prognostic biomarker for ovarian cancer, and the inhibition of 14-3-3ζ could be a therapeutic option that enhances the antitumor activity of cisplatin.
Abstract
Purpose: 14-3-3ζ regulates cell signaling, cell cycle progression, and apoptosis, and its overexpression is associated with disease recurrence and poor clinical outcomes in some solid tumors. However, its clinicopathological role in ovarian cancer is unknown. Our goal was to investigate whether 14-3-3ζ is associated with ovarian cancer prognosis. Materials and Methods: We examined 14-3-3ζ expression by immunohistochemistry in ovarian cancer tissues obtained from 88 ovarian cancer patients. The examined tissues were of various histologies and stages. 14-3-3ζ expression was also analyzed by western blot in seven ovarian cancer cell lines and a primary ovary epithelial cell line. Cell viability was measured using an MTS-based assay following cisplatin treatment. Results: Among the ovarian cancer samples, 53.4% (47/88) showed high 14-3-3ζ expression, and 14-3-3ζ overexpression was positively correlated with more advanced pathologic stages and grades. 14-3-3ζ overexpression was also significantly associated with poor disease-free survival (DFS) and overall survival (OS) of ovarian cancer patients. Median DFS and OS were 1088 and 3905 days, respectively, in the high 14-3-3ζ expression group, but not reached in the low 14-3-3ζ expression group (p=0.004 and p=0.033, log-rank test, respectively). Downregulating 14-3-3ζ by RNA interference in ovarian cancer cells led to enhanced sensitivityto cisplatin-induced cell death. Conclusion: 14-3-3ζ overexpression might be a potential prognostic biomarker for ovarian cancer, and the inhibition of 14-3-3ζ could be a therapeutic option that enhances the antitumor activity of cisplatin.
참고문헌 (18)
- Partridge E, "Results from four rounds of ovarian cancer screening in a randomized trial", Obstet Gynecol, 113, pp.775~782 (2009)[DOI]
- Armstrong DK, "Intraperitoneal cisplatin and paclitaxel in ovarian cancer", N Engl J Med, 354, pp.34~43 (2006)[DOI]
- Markman M, "Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin", J Clin Oncol, 9, pp.389~393 (1991)[DOI]
- Aitken A, "14-3-3 proteins: biological function and domain structure", Biochem Soc Trans, 23, pp.605~611 (1995)[DOI]
- Morrison DK, "The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development", Trends Cell Biol, 19, pp.16~23 (2009)[DOI]
- Tzivion G, "14-3-3 proteins: active cofactors in cellular regulation by serine", threonine phosphorylation, 2002, pp.277, 3061~3064
- Yaffe MB, "How do 14-3-3 proteins work?-Gatekeeper phosphorylation and the molecular anvil hypothesis", FEBS Lett, 513, pp.53~57 (2002)[DOI]
- van Hemert MJ, "14-3-3 proteins: key regulators of cell division, signalling and apoptosis", Bioessays, 23, pp.936~946 (2001)[DOI]
- Tzivion G, "14-3-3 proteins as potential oncogenes", Semin Cancer Biol, 16, pp.203~213 (2006)[DOI]
- Matta A, "Small interfering RNA targeting 14-3-<TEX>$3{\zeta}$<", TEX> increases efficacy of chemotherapeutic agents in head and neck cancer cells, 2010, pp.9, 2676~2688
- Fan T, "Up-regulation of 14-3-3zeta in lung cancer and its implication as prognostic and therapeutic target", Cancer Res, 67, pp.7901~7906 (2007)[DOI]
- Neal CL, "14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival", Cancer Res, 69, pp.3425~3432 (2009)[DOI]
- Watanabe N, "Overexpression of YWHAZ as an independent prognostic factor in adenocarcinoma of the esophago-gastric junction", Am J Cancer Res, 6, pp.2729~2736 (2016)
- Sasaki R, "Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes", Carcinogenesis, 30, pp.423~431 (2009)[DOI]
- 임명철, "Incidence of cervical, endometrial, and ovarian cancer in Korea, 1999-2010", Journal of Gynecologic Oncology, 24(4), pp.298~302 (2013), 대한부인종양학회
- Matta A, "Prognostic significance of head-and-neck cancer biomarkers previously discovered and identified using iTRAQ-labeling and multidimensional liquid chromatography-tandem mass spectrometry", J Proteome Res, 7, pp.2078~2087 (2008)[DOI]
- Li Z, "Downregulation of 14-3-3zeta suppresses anchorage-independent growth of lung cancer cells through anoikis activation", Proc Natl Acad Sci U S A, 105, pp.162~167 (2008)[DOI]
- Ralhan R, "Identification of proteins secreted by head and neck cancer cell lines using LC-MS", MS: strategy for discovery of candidate serological biomarkers, 2011, pp.11, 2363~2376